University of Connecticut

OpenCommons@UConn
Honors Scholar Theses

Honors Scholar Program

Spring 4-28-2021

Utility of Novel Genomic Technologies for Biomarker Identification
in Inflammatory Bowel Disease
Christina Yacoub
christina.yacoub@uconn.edu

Follow this and additional works at: https://opencommons.uconn.edu/srhonors_theses

Recommended Citation
Yacoub, Christina, "Utility of Novel Genomic Technologies for Biomarker Identification in Inflammatory
Bowel Disease" (2021). Honors Scholar Theses. 838.
https://opencommons.uconn.edu/srhonors_theses/838

Utility of Novel Genomic Technologies for Biomarker Identification in
Inflammatory Bowel Disease

Christina Yacoub
University of Connecticut, School of Nursing
NURS 4597W: Senior Thesis in Nursing
Dr. Wendy A. Henderson
April 28, 2021

Abstract
The purpose of this study is to determine whether differences in protein expression exist between
patients with inflammatory bowel disease (IBD), both Crohn’s Disease (CD) and Ulcerative
Colitis (UC), irritable bowel syndrome (IBS), and healthy controls (HC). A total of fourteen
colonic biopsies (n=14, 8-IBD, 4-IBS, 2-HC) underwent nucleus counts using the nCounter
software of the Nanostring GeoMx Digital Spatial Profiler (NanoString Technologies, Inc.,
Seattle, Washington, USA). Three regions of interest were stained according to tryptase, crypt,
and connective tissue and visualization markers were attached to fluoresce thirty inflammatory
and oncological proteins of interest. After nucleus counts for proteins of interest were plotted in
Tableau (2020.4.0), overexpression of AKT, beta-catenin, histone H3, CD44, S6, STAT3 were
apparent for both IBD and IBS. The overexpressed proteins endorse mostly positive correlational
relationships according to the bivariate correlation conducted in IBM SPSS Statistics (Version
27) predictive analysis software. Establishing validated levels of elevated protein expression
offers the clinical opportunity to devise diagnostic biomarkers. Solidifying knowledge of the
relationships between the inflammatory proteins provides potential understanding into the
similarities of IBS and IBD.
Keywords: IBD, Crohn’s Disease, Ulcerative Colitis, IBS, protein expression,
inflammation, oncologic activity, biomarkers
Background
The incidence of inflammatory bowel disease (IBD) has been increasing internationally
with a total of 5.2 million people in North America and Europe currently diagnosed
(Ananthakrishnan et al., 2020). IBD is an autoimmune illness encompassing Crohn’s Disease

(CD) and Ulcerative Colitis (UC) which can vary from mild to severe based on symptoms and
colon integrity. UC is generally superficial, continuous inflammation occurring in the submucosa
of the large intestine whereas CD is transmural inflammation mixed between healthy intestines
that can manifest anywhere in the gastrointestinal tract. The etiology is unknown but a genetic
link has been observed and environmental factors such as smoking, microbiome diversity, oral
contraceptives, antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDS), and
appendectomies have been studied with some correlational evidence (Ko et al., 2014).
More importantly, IBD can induce tissue damage and subsequently, through chronic
inflammation, colon cancer (Beaugerie & Itzkowitz, 2015; Nebbia et al., 2020; Stidham &
Higgins, 2018). Some studies have shown those with IBD are twice as likely to get colorectal
carcinoma compared to healthy individuals (Beaugerie & Itzkowitz, 2015). According to the
American Gastroenterology Association, endoscopy surveillance is recommended every 1-2
years for adults with IBD (Shah & Itzkowitz, 2020). Noninvasive tools such as the Crohn’s
Disease Activity Index, Harvey-Bradshaw Index, and Partial Mayo Scoring Index score the
severity of the disease based on symptomology subjectively reported by patients. However, these
methods of scoring do not provide an accurate picture of what is occurring endoscopically or
histologically making them less than ideal for tracking inflammation (Lewis et al., 2020).
Additionally, serum biomarkers like C-reactive protein (CRP) or erythrocyte sedimentation rate
(ESR) lack sensitivity and do not correlate with inflammation of the bowel wall (Porter et al.,
2020). Fecal calprotectin is able to identify colonic inflammation but does not show small
intestine inflammation (Porter et al., 2020). This leaves colonoscopies or other forms of
endoscopy to be the gold standard in diagnosing and monitoring IBD. It is important to note that
for some patients, it is contraindicated to perform colonoscopies. Studies have shown patients

with IBD are at an 8-fold increased risk of colonoscopy-induced adverse events such as
perforations (Mukewar et al., 2014). Colonoscopies are costly, and demanding procedures
requiring a clear-liquid diet 24 hours before the procedure and a liquid prep to cleanse the colon.
As a result, many patients with IBD are not compliant with surveillance colonoscopies despite
being a high-risk population for developing colon cancer (Davis et al., 2013). Therefore, it is
challenging for clinicians to determine when patients are in remission or in a flare noninvasively.
More biomarkers are needed to adequately assess disease progression as well as response to
pharmaceutical interventions. Inflammatory marker specificity between IBS and IBD is also
needed to avoid unnecessary colonoscopies or misdiagnoses.
IBS is diagnosed based on fulfilling two of the categories on the Rome Criteria. Patients
with abdominal pain once or more per day or week are screened for increased or decreased pain
with defecation, changes in stool frequency, and changes in stool appearance. IBS-C is a
decrease in the number of bowel movements with more solid stools as designated by the Bristol
stool chart. IBS-D refers to an increase in frequency of bowel movements with more loose stools
as designated by six or seven on the Bristol stool chart. Evidently, the symptoms of IBS and IBD
can be similar. IBS is considered the most prevalent functional gastrointestinal disorder yet there
is no biomarker or gold standard of diagnosing IBS (Lacy & Patel, 2017). One study showed
10% of IBD patients were misdiagnosed with IBS for several years (Card et al., 2014).
Treatment for IBS does not address the inflammatory process thus a misdiagnosis prevents
patients from getting adequate care. More biomarkers in the clinical setting would mean an
increase in patient safety through a decrease in invasive procedures, a decrease in healthcare
costs, and greater opportunity for accurate diagnoses.

Introduction
Quantitative protein expression has been a major prospect of cancer research and clinical
biomarker development (McNamara et al., 2021; Mungenast et al., 2021; Kang et al., 2021). The
Nanostring GeoMx DSP has allowed researchers to explore the tumor microenvironment and
generate information regarding cancer development. Previous studies conducted by Galon et al.
(2011) and Bindea et al. (2013), looked at the ratio of the markers CD3 and CD45RO, CD3 and
CD8, or CD8 and CD45RO as colorectal cancer diagnostic measures. The protein ratios can be
further evaluated using GeoMx to confirm significance in cancer progression and thus develop
more specific cancer treatments (Mungenast et al., 2021). The proteins discussed in this paper
include AKT, CD44, STAT3, beta-catenin, histone H3, and S6. AKT, being a protein kinase,
phosphorylates other proteins that can either promote or inhibit certain cell activity. AKT
regulates metabolism, proliferation, cell survival and growth, angiogenesis and the uptake of
glucose into the cell. AKT is a central protein in signal transduction pathways and has been
involved in susceptibility to colon cancers (Bateman et al., 2020). CD44 is a cell-receptor protein
involved in cell adhesion and migration. CD44 plays a pivotal role in the signal transduction
pathway resulting in activation of T-lymphocytes and inflammation (Bateman et al., 2020).
Elevated levels of CD44 have been associated with certain cancers. STAT3 or signal transducer
and activator of transcription 3 mediates cellular response to interleukins and growth factors. It
also regulates the inflammatory response by regulating differentiation of CD4+ T-cells into THelper cells. High levels of STAT3 are associated with certain cancers. Beta-Catenin regulates
cell adhesion as a downstream signal of canonical Wnt pathway. Increased activity of betacatenin is linked to several cancers, including colorectal (Bateman et al., 2020). Histone H3 is a
transcription regulator involved in DNA repair and post-translational modifications. S6 is part of

the small 40S ribosomal subunit which is responsible for cell growth and proliferation (Bateman
et al., 2020). Understanding the cellular pathways of the proteins involved in the inflammatory
and oncogenic process continues to be a focal point of targeted therapy for IBD and cancers.
Methods
Data published by Henderson et al. (2020) was used to compare protein expression
among IBD, IBS and healthy control. IRB approval was not required since data is public and
contains no information that could potentially identify participants. Formalin-fixed paraffin
embedded (FFPE) colonic samples were masked according to three regions of interest, one being
tryptase, two is crypt and the third is connective tissue. The total sample size is fourteen, four
colonic biopsies were taken from patients with IBS, eight from patients with IBD, and two were
from healthy patients. All patients experienced moderate abdominal pain and were untreated
prior to collection of biopsies. Nucleus counts were performed using Nanostring GeoMx Digital
Spatial Profiler (DSP). GeoMx is done by attaching photocleavable oligonucleotides to the 30
inflammatory/oncological proteins’ antibodies and manually staining for the regions of interest
as seen in figure 1. One protein was Rabbit IgG which was used as an internal negative control
because there should be no expression of rabbit antibodies in human samples. Once regions of
interest are stained/fluorescent, the ultraviolet light detaches the oligonucleotides which can then
be placed onto a microtiter plate for the GeoMx DSP software to count. For this analysis the
nuclei counts for the three regions of interest were utilized for comparison. GeoMx is a novel
instrument that allows for the quantification of proteins without damaging the sample or
requiring amplification. The nucleus counts were then separated according to region of interest
and a bivariate correlation between proteins was conducted. Data were then visualized using
Tableau software and proteins appearing overexpressed were run through the String database.

Figure 1

Note. Process of collecting nucleus counts indicated in the protein pathway in the image.
GeoMx(R) Digital Spatial Profiler. (2021). [Illustration]. NanoString.
https://www.nanostring.com/products/geomx-digital-spatial-profiler/geomx-dsp-overview/

Results
The masked FFPE colonic samples for each patient are indicated in Figures 2 through 15.
The nCounter software can quantify protein expression through nucleus counts. Graphs were
created to visualize the data in Figures 16 through 18. The proteins with higher nucleus counts
for each region were included in bivariate correlation Tables 1 through 3.
The results of the visualization conducted on Tableau indicate increased protein
expression for CD44, beta-catenin, STAT3, S6 and histone H3 as seen in Figure 16. In Figure 17
and 18, AKT, beta-catenin, histone H3, STAT3, and S6 had marked increases compared to
healthy control samples. Expression of VISTA was noted only in connective tissue and crypt for
patients with IBD.
The bivariate correlation run through SPSS revealed significant correlation between most
of the proteins. However, when considered with the data visualization, the bivariate correlation
served as a confirmation of positive association between the proteins of interest. However, for
STAT3, positive association was not significant. STAT3 also did not have any relationship with
beta-catenin and histone when run through the String database. Beta-catenin, has experimentally,
database curated and is coexpressed with AKT, All the other proteins have experimental
interactions.

Figure 2
FFPE Fluorescent IBS-5 Slides Masked with Visualization Markers with ROI Circled

Note. A. The red tryptase visualization marker allows for distinguishing the tryptase rich
environment for selection in the image directly below. B. The blue nuclei visualization marker
highlights the crypt microenvironment for protein analysis in the region. C. PanCK green
visualization marker displays the connective tissue environment for protein analysis.
Figure 3
FFPE Fluorescent IBS-10 Slides Masked with Visualization Markers with ROI Circled

Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3
Figure 4
FFPE Fluorescent IBS-4 Slides Masked with Visualization Markers with ROI Circled

Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3
Figure 5
FFPE Fluorescent IBS-1 Slides Masked with Visualization Markers with ROI Circled

Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3
Figure 6
FFPE Fluorescent IBD-6 Slides Masked with Visualization Markers with ROI Circled

Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3
Figure 7
FFPE Fluorescent IBD-19 Slides Masked with Visualization Markers with ROI Circled

Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3
Figure 8
FFPE Fluorescent IBD-18 Slides Masked with Visualization Markers with ROI Circled

Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3
Figure 9
FFPE Fluorescent IBD-7 Slides Masked with Visualization Markers with ROI Circled

Note. A. Tryptase ROI-1, B. Crypt-ROI-2, C. Connective-ROI-3
Figure 10
FFPE Fluorescent IBD-3 Slides Masked with Visualization Markers with ROI Circled

Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3
Figure 11
FFPE Fluorescent IBD-15 Slides Masked with Visualization Markers with ROI Circled

Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3
Figure 12
FFPE Fluorescent IBD-12 Slides Masked with Visualization Markers with ROI Circled

Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3
Figure 13
FFPE Fluorescent IBD-13 Slides Masked with Visualization Markers with ROI Circled

Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3
Figure 14
FFPE Fluorescent Healthy Control-1 Slides Masked with Visualization Markers with ROI
Circled

Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3
Figure 15
FFPE Fluorescent Healthy Control-2 Slides Masked with Visualization Markers with ROI
Circled

Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3

Figure 16
Nucleus Count for Inflammatory and Oncologic Proteins in Tryptase Masked Colonic Samples

Note. Protein nucleus count data for tryptase stained colonic biopsies were plotted in Tableau
software. The x-axis is scaled independently for each patient with ranges of nucleus counts from
0-200. Increased expression of beta-catenin, CD44, histone H3, S6, and STAT3 is comparatively
visible.

Figure 17
Nucleus Count for Inflammatory and Oncologic Proteins in Crypt Masked Colonic Samples

Note. Protein nucleus count data for crypt stained colonic biopsies are visualized. The x-axis is
scaled independently for each patient with ranges of nucleus counts from 0-40. Increased
expression for AKT, beta-catenin, histone H3, S6, and STAT3 is comparatively noted.

Figure 18
Nucleus Count for Inflammatory and Oncologic Proteins in Connective Tissue Masked Colonic
Samples

Note. Protein nucleus count data for connective tissue stained colonic biopsies were inputted into
Tableau for visualization. The x-axis is scaled independently for each patient with ranges of
nucleus counts from 0-40. Increased expression of AKT, beta-catenin, Histone H3, S6, and
STAT3 is comparatively indicated.

Table 1
Tryptase Stained Colonic Samples’ Bivariate Correlation Between Proteins

Measure

1

2

3

4

5

1. Beta-Catenin

--

0.91**

0.91**

0.93**

0.65**

2. CD44

0.91**

--

0.80**

0.75**

0.58

3. Histone H3

0.91**

0.80**

--

0.93**

0.77**

4. S6

0.88**

0.75**

0.93**

--

0.81**

5. STAT3

0.65**

0.58

0.76**

0.81**

--

Note. The 31 proteins (n=31) were inputted into the bivariate correlation through IBM SPSS.
The proteins with elevated expressions noted in Figure 16 from Tableau are listed in the
correlational table. Significant correlation is observed between all the proteins except STAT3
and CD44, with an r value of 0.58 and p value=0.005.
**p<0.001

Table 2
Crypt Stained Colonic Samples’ Bivariate Correlation Between Proteins

Measure

1

2

3

4

5

1. AKT

--

0.815**

0.93**

0.921**

0.604

2. Beta-Catenin

0.815**

--

0.854**

0.872**

0.596

3. Histone H3

0.93**

0.854**

--

0.923**

0.669**

4. S6

0.921**

0.872**

0.923**

--

0.712**

5. STAT3

0.604

0.596

0.669**

0.712**

--

Note. The 31 proteins (n=31) were inputted into the bivariate correlation through SPSS. The
proteins with elevated expressions noted in Figure 17 from Tableau are listed in the correlational
table. STAT3 fails to have significant correlation between AKT and Beta-Catenin with p values
of 0.022 and 0.025, respectively.
**p<0.001

Table 3
Connective Tissue Masked Colonic Samples’ Bivariate Correlation Between Proteins

Measure

1

2

3

4

5

1. AKT

--

0.624

0.853**

0.747**

0.174

2. Beta-Catenin

0.624

--

0.645*

0.562

0.078

3. Histone H3

0.853**

0.645*

--

0.876**

0.228

4. S6

0.747**

0.562

0.876**

--

0.325

5. STAT3

0.174

0.078

0.228

0.325

--

Note. The 31 proteins (n=31) were inputted into the bivariate correlation through SPSS. The
proteins with elevated expressions noted in Figure 18 from Tableau are listed in the correlational
table. A lack of correlation between STAT3 and AKT (p=0.589), beta-catenin (p=0.809),
Histone H3 (p=0.476), and S6 (p=0.303) is evident through elevated p values. Beta-catenin
shows insignificant correlation with AKT and S6 with p value equal to 0.3 and 0.57,
respectively.
*p<0.05
**p<0.001

Figure 19
Visualization of Inflammatory and Oncological Protein Relationships

Note. A. Image includes 23 of the 30 inflammatory or oncogenic proteins run through the String
database. B. The image on the right shows only the proteins that were overexpressed within the
three regions of interest. For both images, the pink line shows the experimentally confirmed
interactions, the black line indicates co-expression, and the blue line represents database curated
interactions. The green line has no significance besides connecting the proteins. AKT and betacatenin (CTNNB1) have the most established relationships.

Discussion
The proteins found to be highly expressed across the regions of interest are generally
responsible for promoting cellular proliferation. Of note is the expression of VISTA seen only in
those with IBD for crypt and connective tissue masked samples thus being an ideal candidate for
future research. VISTA is an immune checkpoint protein that suppresses T-cell activation and
subsequent cytokines (Lines et al., 2014). VISTA could be a potential mechanism to counteract

excessive inflammation and thus was not seen with IBS. Due to the fact that it is only expressed
in certain microenvironments of patients with IBD, it could be used as a biomarker for diagnosis.
GeoMx allows for quantification of proteins in specific colonic regions thus improving
biomarker and cancer research. The efficacy of specific treatments through targeted pathway
inhibition can be explored more easily. It is expected that inflammatory proteins would be
elevated in colonic samples of patients with IBD. However, the patients with IBS also exhibited
increased expression of the same proteins suggesting more research is needed to understand the
pathogenesis of IBS. Moreover, the oncogenic activity of beta-catenin, STAT3, and CD44
provides potential noninvasive colon cancer surveillance. As more research is conducted, these
protein markers can be used to monitor disease progression. Understanding expression of these
proteins can also individualize pharmacological therapies for patients with IBD and determine
efficacy of response to treatment. For instance, tofacitinib (Xeljanz), a JAK/STAT inhibitor, has
evidence of efficacy in patients with ulcerative colitis when anti-tumor necrosis factor blockers
are ineffective. If a patient has elevated STAT3, which was seen in the colonic samples of
patients with IBD, it can be predicted that tofacitinib’s inhibitory effect would lead to a reduction
in inflammation for these patients. Ultimately, knowing which inflammatory proteins are highly
expressed, would indicate to a clinician which inflammatory pathway(s) is/are specifically
activated and therefore prescribe treatment to target it.
Limitations
This research included a small sample size. Only 14 colonic samples were analyzed thus
preventing generalizations and adequate statistical analysis. All proteins discussed in this study
are known inflammatory or oncological proteins therefore a bias is present. The data were also

missing a positive internal control so expression seen could not be compared to a known colonic
protein. Finally, GeoMx DSP is a novel instrument and therefore is not validated.
Conclusion
IBD is increasing internationally with no valid noninvasive methods to diagnose and
monitor the disease. The purpose of this research was to compare protein expression between
IBD, IBS and healthy control using GeoMx DSP to quantify nucleus counts. By researching
protein expression, insight into pathophysiology can be established and thus improve diagnostics
and treatment. The results revealed beta-catenin, CD44, histone H3, S6, STAT3 were
overexpressed in ROI-1 with a strong positive correlation seen with the exception of CD44 with
STAT3. For ROI-2 AKT, beta-catenin, histone H3, S6, STAT3 were overexpressed with a
positive correlation except for STAT3 with beta-catenin and AKT. For ROI-3, AKT, betacatenin, histone H3, S6, STAT3 were overexpressed but STAT3 had no correlation with any of
the other proteins. In general, these proteins are involved in cellular growth and proliferation
making them practical to observe in the future in relation to IBD. Individualizing therapies based
on the guidance of biomarkers would increase quality of treatment and decrease the trial and
error of bottom-up treatment. More biomarkers are needed to address the deficiency of
diagnostic options, the steep cost, and dangers of endoscopy.
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